Vitamin D and Zinc Levels in Patients Undergoing Ergometry Test
Recruitment status was: Active, not recruiting
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Vitamin D and Zinc Levels in Patients Undergoing Ergometry Test|
- positive stress test [ Time Frame: one year ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||March 2010|
|Estimated Study Completion Date:||March 2011|
|Estimated Primary Completion Date:||March 2011 (Final data collection date for primary outcome measure)|
positive ergometry as specified by a cardiologist on site.
negative ergometry as specified by cardiologist on site.
patients with positive stress test
100 patients with positive ergometry test as specified by the cardiologist in charge. All patients are ambulatory patients referred for routine check up.
Hypovitaminosis D is generally defined as 25(OH)D levels of < 20ng/ml, while levels of 21-29ng/ml indicate insufficiency and those above 30ng/ml are regarded as sufficient.
The rational behind the observations associating vitamin D deficiency with CVD is that on the one hand, hypovitaminosis D was found to be associated with traditional risk factors such as hypertension (HTN),diabetes mellitus (dm),obesity, dyslipidemia and metabolic syndrome , on the other hand, experimental data demonstrated that vitamin D could affect cardiac muscle cells directly, control parathyroid (PTH) hormone secretion, regulate the rennin- angiotensin- aldosterone system and the immune system, all of which could influence cardiovascular risk.
Epidemiological studies further support this association, demonstrating high prevalence of hypovitaminosis D among U.S. adults with cardiovascular disease (74%). An association between low vitamin D levels and increased myocardial infarction risk as well as total mortality has been also observed.
Low 25hydroxyvitamin D[ 25(OH)D] levels were also independently associated with all cause and CVD mortality among patients scheduled for coronary catheterization.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01080274
|Assaf Harofeh Mc|